People · Operator
Named in public records as an officer, director or promoter · active 2013–2022 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Corvium, Inc. | — | Other | Series A | $38.4M | $30.1M | 2013 |
| Xeno Biosciences Inc. | — | Biotechnology | Series A | $12.1M | $16.4M | 2018 |
Michael Koeris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Koeris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Bloch | 1 | 15 |
| Jeffrey Bussgang | 1 | 7 |
| Jon Karlen | 1 | 7 |
| Micah Rosenbloom | 1 | 6 |
| Andrew Ziolkowski | 1 | 5 |
| Tim Curran | 1 | 5 |
| Stephen Chang | 1 | 5 |
| Jeffrey Arnold | 1 | 5 |
| Stan Rose | 1 | 3 |
| Andy Ziolkowski | 1 | 3 |
| Guy Broadbent | 1 | 3 |
| Timothy Lu | 1 | 2 |
| Jeffrey Swartz | 1 | 2 |
| Sam Kass | 1 | 1 |
| David Beno | 1 | 1 |
| Tom Hughes | 1 | 1 |
| Hasan Celiker | 1 | 1 |
| Jeff Massa | 1 | 1 |
| Kendall Allomer | 1 | 1 |
| Karen Shoemaker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.